MedTrace Logo

e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most

NCT07454824 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-04

No results posted yet for this study

Summary

The overarching goal of this study is to pilot an intervention in which older adults with mild cognitive impairment and dementia and the older adult's care partners are identified in primary care and provided with educational materials through the patient portal to engage the participant in deprescribing. The multicomponent intervention, e-Align, includes delivery of educational information through the patient portal, and a pharmacist-led intervention to align medications with patient and care partner goals and reduce use of central nervous system (CNS) potentially inappropriate medicines (PIM). This work will establish the preliminary data, methods, and partnerships to undertake a multisite embedded pragmatic clinical trial. The resulting triadic-based behavioral intervention will promote patient and care partner engagement, and foster care that aligns with patients' values, and promote improved health and well-being outcomes for people with cognitive impairment and the patient's care partners through deprescribing.

Conditions

  • Dementia
  • Potentially Inappropriate Medication Use
  • Mild Cognitive Impairment (MCI)

Interventions

OTHER

e-ALIGN Patient-Portal Deprescribing

The intervention will consist of educational materials about deprescribing, which will be sent to the patient prior to the scheduled primary care visit.

Sponsors & Collaborators

Principal Investigators

  • Ariel Green, MD, MPH, PhD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2026-08-01
Completion
2026-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07454824 on ClinicalTrials.gov